Press Release

View printer-friendly version Back

Lantheus Medical Imaging, Inc. to Present Data on Cardiovascular PET Imaging Pipeline Candidates at SNM Annual Meeting

-- Company’s Novel Imaging Agents in Development for Evaluation of Coronary
Artery Disease and Heart Failure to be Featured in 14 Presentations

N. BILLERICA, Mass. (May 19, 2010)Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that 14 new abstracts from two of the company’s Positron Emission Tomography (PET) products in development will be presented at the SNM 57th Annual Meeting, being held June 5-9, 2010 in Salt Lake City. Preliminary data from a Phase 2 study on flurpiridaz F 18 (formerly known as BMS747158), a myocardial perfusion PET imaging agent to diagnose coronary artery disease, and Phase 1 data on LMI1195, an innovative cardiac neuronal PET imaging agent, will be featured in a series of oral and poster presentations at the meeting.

“The amount of data on two of our PET cardiac imaging candidates that will be presented at this year’s SNM annual meeting highlights the progress and commitment of Lantheus in advancing our pipeline. We are pleased to be able to share this information with the scientific community,” said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging, Inc. “The fact that SNM has chosen to feature 14 of our abstracts is a testament to the growing interest in the value of PET technology for cardiac imaging. We believe that flurpiridaz F 18 and LMI1195 have the potential to transform how patients with coronary artery disease or heart failure are evaluated and treated.”

The schedule and abstract information for the presentations are listed below.

Presentations featuring flurpiridaz F 18:

  •   Oral Session: “Comparison of myocardial stress perfusion defect assessment using 99mTc sestamibi SPECT vs BMS747158 PET,” Monday, June 7, 10:00-11:30 a.m. (Reference # 798032)
  • Oral Session: “High definition cardiac perfusion PET using a new F-18 imaging agent (BMS747158),” Monday, June 7, 10:00-11:30 a.m. (Reference # 797622)
  • Poster Session: “Automatic 3D intra-scan registration of dynamic BMS747158 myocardial perfusion PET for patient motion correction,” Monday, June 7, 3:15-4:00 p.m. (Reference # 799067)
  • Oral Session: “Simplified quantification of myocardial blood flow with 18F BMS-747158-02: Comparison to kinetic modeling and microspheres in a pig model,” Monday, June 7, 4:30-6:00 p.m. (Reference # 797042)
  • Oral Session: “Cardiac phantom simulation of dose injection parameters for one-day rest/stress myocardial perfusion (MPI) PET imaging with BMS747158 tracer,” Tuesday, June 8, 8:00-9:30 a.m. (Reference # 796392)
  • Poster Session: “Automatic registration of F-18 labeled BMS-747158 stress and rest myocardial perfusion images using 6D cross-correlation optimization,” Tuesday, June 8, 3:15-4:00 p.m. (Reference # 799099)
  • Poster Session: “F-18 labeled BMS747158 PET myocardial perfusion imaging identifies more severe and extensive stress induced myocardial ischemia than Tc-99m sestamibi SPECT,” Tuesday, June 8, 3:15-4:00 p.m. (Reference # 798320)
  • Oral Session: “Enhanced dual gated cardiac perfusion PET using a new F-18 imaging agent (BMS747158),” Wednesday, June 9, 8:00-9:30 a.m. (Reference # 796701)
  • Oral Session: “Development of a method for the determination of dose ratio and minimum inter-injection interval for a one-day rest-stress protocol with BMS747158 PET myocardial perfusion agent,” Wednesday, June 9, 9:45-11:15 a.m. (Reference # 798451)


Presentations featuring LMI1195:

  • Poster Session: “Quantification of normal pattern of regional myocardial uptake of 18F LMI1195 a novel tracer for imaging myocardial sympathetic function: First-in-human study,” Monday, June 7, 3:15-4:00 p.m. (Reference # 798819)
  • Oral session: “Cardiac imaging and uptake mechanism of 18F LMI1195, a novel PET cardiac neuronal imaging agent,” Monday, June 7, 4:30-6:00 p.m. (Reference # 796197)
  • Poster session: “Radiation dosimetry of LMI1195, first-in-human study of a novel F-18 labeled tracer for imaging myocardial innervation,” Tuesday, June 8, 2:30-3:15 p.m. (Reference # 797609)
  • Poster session: “Dosimetry in nonhuman primates of [18F]LMI1195, a novel PET tracer for imaging the cardiac sympathetic nervous system,” Tuesday, June 8,    2:30-3:15 p.m. (Reference # 796608)
  • Poster session: “18F PET imaging of cardiac sympathetic denervation with LMI1195, a new neuronal imaging agent,” Tuesday, June 8, 3:15-4:00 p.m. (Reference # 795716)


About Flurpiridaz F 18 and Coronary Artery Disease
Flurpiridaz F 18, a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1), is designed to be a novel myocardial perfusion PET imaging agent for the diagnosis of coronary artery disease (CAD). Flurpiridaz F 18 has recently completed Phase 2 clinical trials. CAD is the leading cause of death in the United States for both men and women1. Each year, more than half a million Americans die from CAD1.

Phase 1 studies indicated that flurpiridaz F 18 is well-tolerated and demonstrates radiation dosimetry that is comparable to, or less than, that of other PET imaging agents. The data also showed high myocardial uptake at rest that significantly increased with pharmacologically induced stress as well as a ratio of myocardial to background uptake that was favorable and improved over time, suggesting strong potential as a myocardial perfusion PET imaging agent for patients both at rest and under stress.

About LMI1195 and Heart Failure
LMI1195 is a novel F-18 small molecule tracer designed to use molecular imaging and PET technology to improve imaging of cardiac neuronal function. LMI1195 is currently in Phase 1 clinical trials. In preclinical studies, LMI1195 showed promise as a heart failure imaging agent with high cardiac sympathetic nervous system uptake.

Heart failure is a serious medical condition, in which the heart muscle progressively loses its ability to pump blood, which affects more than five million people in the United States and results in about 300,000 deaths each year2.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit

1. National Institutes of Health, National Heart, Lung, and Blood Institute. Coronary Artery Disease: Who Is At Risk.
2. National Institutes of Health, National Heart, Lung, and Blood Institute. Heart Failure: What is Heart Failure?